The Effects of Exercise Snacks on Endothelial Function and Body Composition in Overweight Individuals
22 de abril de 2026 atualizado por: Weifang Medical University
This randomized controlled trial investigates the effects of two types of stair-climbing exercise snacks versus moderate-intensity continuous training on vascular health, body composition, and blood lipids in overweight or obese adults.
Participants will be assigned to one of four groups for 6-8 weeks.
The control group receives no exercise intervention.
Primary outcomes include endothelial function (ultrasound), body composition (InBody), and lipid profile (blood test).
Visão geral do estudo
Status
Ainda não está recrutando
Condições
Descrição detalhada
This is a parallel group randomized controlled trial, with the study subjects being overweight or obese adults (with a body mass index of ≥ 24 kg/m²). Participants will be recruited from universities and randomly assigned to one of the following four groups:
Short-term stair climbing exercise group Participants climbed the stairs 4 to 5 times a day, each time ascending 5 floors (approximately 1 minute each time). There was at least a 1-hour interval between each exercise session, and the exercises were carried out during daily activities. They exercised 3 to 5 times a week for 6 to 8 weeks.
Long-term stair climbing nutrition supplementation group The participants also conducted 4 to 5 stair climbing training sessions every day. Each training session consisted of 3 sets of climbing 5 floors (the total climbing height for each training session was 15 floors), with a rest period of no more than 1 minute between each set. The interval between two training sessions was no less than 1 hour. They exercised 3 to 5 times a week for 6 to 8 weeks.
Moderate-intensity continuous training group (MICT) Participants engaged in 30-minute moderate-intensity running (including warm-up and cool-down activities) each time, 3 to 5 times a week, for 6 to 8 weeks.
Control group Participants maintained their daily activities and did not receive any exercise intervention measures.
Result measurement indicators:
Vascular health: Assessing endothelial function through ultrasound measurement of flow-mediated vascular dilation (FMD).
Body composition: Measured using the InBody body bioelectrical impedance analyzer (including muscle mass, fat mass and body fat percentage).
Blood lipid test: Collect fasting blood samples and measure low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and total cholesterol (TC).
Measurement time points: Measurements were conducted at the baseline (at the beginning of the study), 3-4 weeks (during the intervention period), and 8 weeks (after the intervention ended).
This research protocol has been approved by the Institutional Review Board of Shandong Second Medical University. All participants are required to sign a written informed consent form.
Tipo de estudo
Intervencional
Inscrição (Estimado)
60
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: XINCHEN ZHANG
- Número de telefone: +8615094866869
- E-mail: zhangxinchen2001@126.com
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Age: 18-35 years old (male, female);
- Clear consciousness, stable vital signs;
- Able to understand and follow simple instructions;
- No regular exercise for at least 3 months;
- BMI ≥ 24 kg/m2.
Exclusion Criteria:
- There are other serious diseases, such as tumors;
- There are other neurological diseases;
- There are serious diseases that simultaneously affect the heart, liver, kidneys, endocrine system or hematopoietic system;
- There is a history of alcohol or drug abuse;
- Participated in other clinical trials that might affect the results of this study;
- There are other neurological or musculoskeletal diseases, with pain worsening with exercise;
- It is forbidden to engage in physical training.
- Within the past 3 months, there have been acute cardiovascular events such as acute myocardial infarction,unstable angina pectoris, severe arrhythmia, acute heart failure, etc.；
- Uncontrolled hypertension；
- Severe pulmonary diseases, such as uncontrolled asthma, acute exacerbation of chronic obstructive pulmonary disease, interstitial lung disease with significant exercise limitation；
- Severe joint and bone diseases, acute soft tissue injuries, fractures that have not healed, etc., making it impossible to complete the prescribed exercise load；
- Presence of bleeding tendencies, coagulation dysfunction, or within the past 1 month, there has been major bleeding or a history of surgery；
- The investigator judges that there are any other situations that may affect the safety of the subjects or the results of the trial.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Short-term stair climbing exercise snack group
Participants perform short climbs of the stairs 4 to 5 times a day.
Each climb involves going up 5 floors (approximately 1 minute), and there is a minimum interval of at least 1 hour between each climb.
|
Adopt a fragmented approach, climbing stairs 4-5 times a day, each time climbing 5 floors (approximately 1 minute per session), with at least 1 hour of interval between each session, and spread throughout the daily activity periods.
Exercise 3-5 days per week for a total of 6-8 weeks.
|
|
Experimental: Long-duration stair climbing exercise snack group
Participants climbed the ladder 4 to 5 times a day.
Each climb consisted of 2 to 3 sets (each set involved climbing 5 floors, with a rest period of no more than 1 minute between sets), and the total number of floors climbed in a single session was 10 or 15.
|
On the basis of climbing stairs 4 to 5 times a day, increase the single exercise volume: complete 2 or 3 sets of climbing 5 floors of stairs each time (that is, the total number of floors climbed each time is 10 or 15), with no more than 1 minute of rest between sets.
The intervals between each exercise should be at least 1 hour.
Exercise 3 to 5 days a week, for a total of 6 to 8 weeks of intervention.
|
|
Experimental: Moderate-intensity continuous exercise
The participants engaged in moderate-intensity running training for 3 to 5 days per week, with each session lasting for 30 minutes.
|
Exercise 3 to 5 days per week for a total of 6 to 8 weeks.
Perform 30 minutes of moderate-intensity running training every day.
|
|
Sem intervenção: control group
The participants did not undergo any form of exercise intervention and maintained their usual activity patterns.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Flow-mediated dilation (FMD, relative percentage)
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Flow-mediated dilation expressed as a percentage of the baseline brachial artery diameter.Unit of Measure: %
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Body fat mass
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Body fat mass measured by bioelectrical impedance analysis (InBody device).
Unit of Measure: kg
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Time to peak dilation
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Time required to reach maximal dilation after cuff deflation.Unit of Measure: seconds
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Basal brachial artery diameter
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Baseline diameter of the brachial artery before cuff inflation.Unit of Measure: mm
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Peak brachial artery diameter
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Maximal diameter of the brachial artery after reactive hyperemia.Unit of Measure: mm
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Absolute flow-mediated dilation (FMDabs)
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Absolute change in diameter, calculated as peak diameter minus basal diameter.Unit of Measure: mm
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Standardized FMD
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Flow-mediated dilation adjusted for relevant covariates (e.g., shear stress, baseline diameter) according to standard protocols.Unit of Measure: %
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Body weight
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Body weight measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Body fat percentage
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Body fat percentage measured by bioelectrical impedance analysis (InBody device).Unit of Measure: %
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Body mass index (BMI)
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Body mass index calculated from weight and height measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg/m²
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Basal metabolic rate (BMR)
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Basal metabolic rate estimated by bioelectrical impedance analysis (InBody device).Unit of Measure: kcal
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Waist circumference
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Waist circumference measured by bioelectrical impedance analysis (InBody device).Unit of Measure: cm
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Visceral fat area
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Visceral fat area measured by bioelectrical impedance analysis (InBody device).
Unit of Measure: cm²
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Skeletal muscle mass
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Skeletal muscle mass measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Systolic blood pressure (SBP)
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Systolic blood pressure measured using an electronic sphygmomanometer.Unit of Measure: mmHg
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Serum high-density lipoprotein (HDL) cholesterol concentration
Prazo: Measured at baseline and post-intervention (after 6-8 weeks).
|
Fasting serum HDL cholesterol concentration measured from blood samples.
Unit of Measure: mmol/L
|
Measured at baseline and post-intervention (after 6-8 weeks).
|
|
Diastolic blood pressure (DBP)
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Diastolic blood pressure measured using an electronic sphygmomanometer.
Unit of Measure: mmHg
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Heart rate
Prazo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
Heart rate measured using an electronic sphygmomanometer.Unit of Measure: bpm (beats per minute)
|
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
|
|
Serum low-density lipoprotein (LDL) cholesterol concentration
Prazo: Measured at baseline and post-intervention (after 6-8 weeks).
|
Fasting serum LDL cholesterol concentration measured from blood samples.
Unit of Measure: mmol/L
|
Measured at baseline and post-intervention (after 6-8 weeks).
|
|
Serum total cholesterol concentration
Prazo: Measured at baseline and post-intervention (after 6-8 weeks).
|
Fasting serum total cholesterol concentration measured from blood samples.
Unit of Measure: mmol/L
|
Measured at baseline and post-intervention (after 6-8 weeks).
|
|
HDL/LDL cholesterol ratio
Prazo: Measured at baseline and post-intervention (after 6-8 weeks).
|
Ratio of serum HDL cholesterol to LDL cholesterol calculated from fasting blood samples.Unit of Measure: ratio (dimensionless)
|
Measured at baseline and post-intervention (after 6-8 weeks).
|
|
Serum triglyceride concentration
Prazo: Measured at baseline and post-intervention (after 6-8 weeks).
|
Fasting serum triglyceride concentration measured from blood samples.Unit of Measure: mmol/L
|
Measured at baseline and post-intervention (after 6-8 weeks).
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: YANXIA WANG, PhD, Weifang Medical University(Renamed Shandong Second Medical University)
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
16 de abril de 2026
Conclusão Primária (Estimado)
16 de junho de 2026
Conclusão do estudo (Estimado)
20 de julho de 2026
Datas de inscrição no estudo
Enviado pela primeira vez
13 de abril de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
22 de abril de 2026
Primeira postagem (Real)
30 de abril de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
30 de abril de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
22 de abril de 2026
Última verificação
1 de abril de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026YX160
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .